Therefore, it is recommended for considering PDL-1, CTLA-4, PD-1, FOXP3, MIC-B, miR-155, and miR-195 in the diagnosis and evaluation of the clinical and immunological status of BC patients, who are eligible for targeted immunotherapy. This evidence concerns the gene PDCD1 and breast cancer.